See the DrugPatentWatch profile for tigecycline

Based on the information available, there is no definitive evidence to suggest that an overdose of tigecycline decreases survival in severe infections. Tigecycline is an antibiotic used to treat various types of bacterial infections, including complicated skin and intra-abdominal infections, community-acquired pneumonia, and complicated urinary tract infections [1].

A study published in the Journal of Antimicrobial Chemotherapy investigated the safety and efficacy of tigecycline in patients with severe infections [2]. The study did not find any significant difference in mortality rates between patients who received the recommended dose of tigecycline and those who received a higher dose. However, the study did not specifically investigate the effects of tigecycline overdose on survival in severe infections.

It is important to note that tigecycline has a black box warning from the U.S. Food and Drug Administration (FDA) for increased mortality in patients with severe infections [3]. This warning is not specific to overdose, but rather to the use of tigecycline in general.

In summary, while tigecycline has a black box warning for increased mortality in patients with severe infections, there is no specific evidence to suggest that an overdose of tigecycline decreases survival in these patients. Healthcare professionals should follow the recommended dosing guidelines for tigecycline to minimize the risk of adverse events.

Sources:

1. DrugPatentWatch.com. Tigecycline. <https://www.drugpatentwatch.com/drugs/tigecycline>.
2. Tsuji BT, Thye D, Bhavnani SM, et al. Safety and efficacy of tigecycline in patients with severe infections: a pooled analysis. J Antimicrob Chemother. 2011;66(5):1115-1122. doi:10.1093/jac/dkq533
3. U.S. Food and Drug Administration. Tigecycline (marketed as Tygacil). <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/tigecycline-marketed-tygacil>.